Date:8/3/2009

ses: 61% 22,801 78% 29,999 ------ ------ Operating loss -5% (1,798) -28% (10,710) ----- ------ Other income (expense): Interest income 0% 8 0% 91 Interest expense -2% (632) -1% (423) Gain on foreign currency 1% 197 0% 144 Other income, net 1% 191 0% 67 --- -- Other (expense) income, net -1% (236) 0% (121) --- --- Loss before provision for income taxes -5% (2,034) -28% (10,831) Provision for income taxes 2% 716 2% 654 --- --- Net loss -7% $(2,750) -30% $(11,485) ======= ======== Loss per share: Basic and diluted $(0.09) $(0.39) ====== ====== Weighted average shares outstanding: Basic and diluted 30,276 29,488 ====== ====== STAAR Surgical Company Global Sales (in 000's) Unaudited Three Months Ended Six Months Ended ------------------ ---------------- July 3, June 27, % July 3, June 27, % Geographic Sales 2009 2008 Change 2009 2008 Chang
'/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine news :

1. STAAR Surgical to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York
2. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
3. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
4. STAAR Surgical Announces Second Quarter 2009 Earnings Release Date And Conference Call
5. Richard A. Meier Appointed to STAAR Surgical Board of Directors
6. STAAR Surgical Completes Common Stock Offering
7. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
8. STAAR Surgical Announces First Quarter 2009 Earnings Release Date and Conference Call
9. STAAR Surgical Reports 14% Fourth Quarter Revenue Growth
10. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
11. STAAR Surgical Reports 33% Third Quarter Revenue Growth